Highlights

  • Avecho's independent Data Safety Monitoring Board recommended continuation of its Phase III insomnia trial without increasing planned enrolment.
  • The interim analysis reviewed 244 participants across CBD 75mg, CBD 150mg and placebo groups with no serious adverse events identified.
  • The trial remains focused on supporting a potential Therapeutic Goods Administration registration pathway for Avecho's CBD capsule.
  • Avecho received approximately A$1.9 million from option exercises in May 2026 to support ongoing development activities.

Avecho Biotechnology (ASX:AVE) has cleared a key milestone in its Phase III insomnia program after an independent Data Safety Monitoring Board (DSMB) recommended the study continue to its full planned enrolment of 519 participants without increasing patient numbers.

The interim review assessed safety data and trial variability rather than final treatment effectiveness. The study remains blinded, meaning the company and investors do not yet know whether the cannabidiol (CBD) capsule delivers a statistically significant benefit compared with placebo.

For Avecho (ASX:AVE), the outcome reduces the possibility of additional recruitment requirements and supports continuation of the existing trial design as the company progresses toward final efficacy results.

What Was Announced?

On 24 June 2026, Avecho announced that the DSMB overseeing its Phase III insomnia trial had completed a planned interim analysis involving 244 randomised participants across three treatment groups: 75mg CBD, 150mg CBD and placebo.

The trial is evaluating Avecho's proprietary TPM (tocopheryl phosphate mixture)-enhanced CBD soft-gel capsule, administered nightly for eight weeks in adults with chronic insomnia.

The multicentre, randomised, double-blind, placebo-controlled study has been designed to support a potential Therapeutic Goods Administration (TGA) registration submission.

An interim analysis allows an independent committee of clinicians and biostatisticians to review safety and statistical assumptions without revealing treatment allocation. The DSMB can recommend continuation, sample-size adjustment or trial discontinuation.

In this case, the committee recommended the trial continue to the planned 519 participants without modification.

Why This Matters

Avoiding a sample-size increase can reduce additional recruitment costs and delays while maintaining the original trial framework.

For Avecho (ASX:AVE), the DSMB outcome indicates that treatment effect assumptions and data variability remain aligned with the original trial design. However, the review does not confirm efficacy, and the final clinical outcome will depend on the full dataset after completion of enrolment.

The company continues to target a potential registration pathway for its CBD insomnia treatment, with final top-line efficacy results remaining the key upcoming milestone.

Company Background

Avecho Biotechnology is an ASX-listed Melbourne-based drug delivery and formulation company focused on its patented TPM technology, which is designed to improve absorption and bioavailability of poorly water-soluble compounds.

The company's lead program applies TPM technology to a CBD soft-gel capsule for chronic insomnia.

In 2025, Avecho entered a licensing agreement with Sandoz AG covering the Australian market. The agreement included a US$3 million upfront payment, potential milestone payments of up to US$16 million and tiered royalties on future net sales.

The Partnership supports Avecho's Australian commercialisation strategy while the company continues discussions for additional regional opportunities.

Financial Position

Avecho reported cash of approximately A$4.3–4.4 million as at 31 March 2026, with quarterly operating cash outflow of around A$887,000.

In May 2026, expiry of listed options generated approximately A$1.9 million through option exercises at $0.012 each, increasing the company's pro-forma cash position to approximately A$6.3 million.

Avecho has indicated the funds will support ongoing licensing discussions and further trial activities.

The company remains a pre-revenue biotechnology Business and continues to rely on licensing arrangements, funding activities and available cash resources to support development.

What Comes Next?

Following the DSMB review, Avecho's immediate focus is completing recruitment of the remaining participants required to reach the 519-person enrolment target.

Management expects the recruitment process to take approximately 12 months and plans to use additional clinical trial sites to support enrolment.

Future milestones include completion of the Phase III trial, release of final unblinded efficacy results, discussions with regulators including the TGA, and potential additional licensing agreements beyond the existing Sandoz Australian arrangement.

Risks

Avecho (ASX:AVE) remains exposed to clinical development risk, as the DSMB review confirmed safety and trial continuation but did not establish efficacy. The Phase III study could still Fail to demonstrate a statistically significant benefit compared with placebo. The company also operates with a limited cash balance and may require additional funding if licensing Revenue is delayed. Regulatory approval remains uncertain, and reliance on commercial partners such as Sandoz creates additional execution and timing risks.

Investor Takeaway

The DSMB recommendation allows Avecho (ASX:AVE) to continue its Phase III insomnia trial without increasing enrolment requirements, reducing one potential source of delay and additional cost.

However, the interim review does not confirm whether the CBD capsule will demonstrate clinical benefit. The final outcome depends on completion of recruitment and analysis of the full trial dataset.

Avecho's Sandoz partnership and recent option exercise proceeds provide funding support, but the company remains dependent on clinical, regulatory and commercial milestones as it progresses toward potential product registration.